Cytomegalovirus secondary prevention: Difference between revisions
Jump to navigation
Jump to search
No edit summary |
No edit summary |
||
| Line 5: | Line 5: | ||
==Secondary Prevention== | ==Secondary Prevention== | ||
Recommendations for pregnant women with regard to CMV infection: | Recommendations for pregnant women with regard to CMV infection: | ||
*Laboratory testing for [[antibody]] to CMV can be performed to determine if a women has already had CMV infection. | |||
*Women who develop a [[mononucleosis]]-like illness during pregnancy should be evaluated for CMV infection and counseled about the possible risks to the unborn child. | *Women who develop a [[mononucleosis]]-like illness during pregnancy should be evaluated for CMV infection and counseled about the possible risks to the unborn child. | ||
*Recovery of CMV from the [[cervix]] or [[urine]] of women at or before the time of [[delivery]] does not warrant a [[cesarean section]]. | *Recovery of CMV from the [[cervix]] or [[urine]] of women at or before the time of [[delivery]] does not warrant a [[cesarean section]]. | ||
Revision as of 15:07, 14 December 2012
Template:Cytomegalovirus Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]
Secondary Prevention
Recommendations for pregnant women with regard to CMV infection:
- Laboratory testing for antibody to CMV can be performed to determine if a women has already had CMV infection.
- Women who develop a mononucleosis-like illness during pregnancy should be evaluated for CMV infection and counseled about the possible risks to the unborn child.
- Recovery of CMV from the cervix or urine of women at or before the time of delivery does not warrant a cesarean section.
- The demonstrated benefits of breast-feeding outweigh the minimal risk of acquiring CMV from the breast-feeding mother.
- There is no need to either screen for CMV or exclude CMV-excreting children from schools or institutions because the virus is frequently found in many healthy children and adults.
Patients without CMV infection who are given organ transplants from CMV-infected donors should be given prophylactic treatment with valganciclovir (ideally) or ganciclovir and require regular serological monitoring to detect a rising CMV titre, which should be treated early to prevent a potentially life-threatening infection becoming established.